Pfizer scans India for shopping options

October 22nd, 2009|

Pfizer has approached several Indian drugmakers for possible alliances as part of moves to try and bolster revenues threatened by the expiry of patents on key blockbuster drugs in the next three years, three persons with direct knowledge of the matter said.

India govt seeks Argentina to ease trade policy to increase pharma trade

October 14th, 2009|

The Minister of State for Defence Dr. M. M Pallam Raju has sought the Argentine president Cristina Fernandes de Kirchner to ease the country's pharma import policy to allow easy access for Indian pharmaceutical companies to the Argentine market, in order to increase the pharma trade between the two countries.

Pharma cos likely to emerge stronger in Q2

October 13th, 2009|

The pharma sector is poised to emerge as one of the best-performing sectors in terms of its performance for the September quarter.

Indian pharma market set to grow 12 to 15 percent

October 11th, 2009|

The domestic pharma market will outshine the global market, growing at a compounded annual rate of 12-15% as against a global average of 4-7% during 2008-2013.

Big Pharma targets emerging mkts

October 11th, 2009|

GlaxoSmithKline (GSK) announced a joint venture in China for the manufacture and distribution of vaccines in the region. This was the second such alliance for GSK this year in that country. In June, the company had signed an agreement with a Chinese biotech company to develop and manufacture flu vaccines.

Glaxo eyes Dr Reddys as Big Pharma hunts in India

October 7th, 2009|

Western drugmakers are stepping up the hunt for emerging market "tigers" in India.

Pharma enters emerging markets via generics

October 7th, 2009|

Major pharmaceutical companies see generics as a bridge to the futureMOST PHARMACEUTICAL innovators treat patent expiry like a terminal disease and the generics business as a sort of hospice where dying products ease into commodity oblivion, but recent deals and acquisitions suggest growing faith in an afterlife of emerging markets.

Growth in US, local market to pep up DRL

October 6th, 2009|

Dr Reddy’s Laboratories (DRL), India’s third-largest pharma company, has seen a sharp rise of 25% in its stock price over the past fifteen trading sessions.

Drug MNCs look at India as a market

October 6th, 2009|

The list of drug majors scouting for a suitable buy in India is long. But this time, the attraction is: India as a market, and not merely as an inexpensive destination to source and produce products, say consultants and lawyers observing the increased merger and acquisition (M&A) activity seen in the pharmaceutical space.

Pharmac India 2009 to be held in Ahmedabad from Nov 7 to 9

September 29th, 2009|

The Indian Drug Manufacturers Association Gujarat State Board (IDMA -GSB) is organising India's largest pharma & healthcare exhibition 'Pharmac India 2009' in Ahmedabad from November 7 to 9. While Pharmexcil is the co-organiser of the event, it is supported by Federation of Pharma Entrepreneurs (FOPE), Sabarkantha District Drug Manufacturers Association, BDMA and Rajasthan Pharmaceutical Manufacturers Association.

Abbott to acquire Solvay Pharmaceuticals for US dollar 6.6 bn

September 28th, 2009|

American healthcare major Abbott Laboratories today said it will buy pharma business of Belgium-based Solvay Group for USD 6.6 billion.

Growing pharma market makes India a clinical trial destination: Report

September 28th, 2009|

The domestic pharmaceutical market is expected to triple to $20 billion by 2015 from the current $7 billion and move into the world’s top 10 markets.

Mega deals boost pharma in crisis

September 14th, 2009|

Following the collapse of Lehman Brothers and the global meltdown, pharmaceuticals is perhaps the only sector globally which withstood it all, announcing a slew of deals month after month.

Pfizer plans major push into generics

September 10th, 2009|

Pfizer Ltd, the Indian subsidiary of the world’s largest drug maker Pfizer Inc., is making an aggressive play in the Indian generics or off-patent drugs market.

Pharma cos will require DCGI nod for exports

September 6th, 2009|

Domestic pharmaceutical companies will not be able to export medicines without the approval of central drug regulator Drug Controller General of India (DCGI) from next month, a Health ministry official said. The move is on the lines of the World Health Organisation’s (WHO) directive that discourages multiple certifying authorities in one country.

India pharmaceutical market currently ranks 13th among the major global markets

August 24th, 2009|

India’s per capita healthcare expenditure is well below international recommendations and compares poorly with the other emerging economies (Brazil, Russian Federation, China, Republic of Korea, Turkey and Mexico). Despite an improvement in the country’s healthcare infrastructure over the recent past, there remains a lack of health centers and shortage of health personnel.

North Indian Pharma: Focusing on R and D and Tie-ups to Meet Challenging conditions

August 24th, 2009|

The North India based listed pharmaceutical companies have established strong presence in the domestic market, highly regulated markets and emerging markets during the last couple of years with several US FDA approved facilities, high-tech R&D laboratories, focus on new lifestyle drugs and partnership with international giants.

Pharma body questions proposal to boost exports

August 23rd, 2009|

Indian Pharmaceutical Alliance (IPA), the apex body representing domestic pharma companies, is up in arms against the government’proposed action plan to boost drug exports. The department of pharmaceuticals (DoP) has proposed funding by venture capitalists (VCs), service tax exemptions, import duty waiver on pharmaceutical products and protection to clinical test data to boost exports.

Big pharma companies join outsourcing queue

August 18th, 2009|

India emerging as a big global destination for contract manufacturing, unlike R&D outsourcing

India a preferred destination for clinical trials

August 8th, 2009|

The cost advantage is luring many pharma companies to prefer India as the destination for contract research and clinical trials to the developed markets, according to a study.